Publication | Closed Access

Early metabolic response to neoadjuvant letrozole, measured by FDG PET/CT, is correlated with a decrease in the Ki67 labeling index in patients with hormone receptor-positive primary breast cancer: a pilot study

Breast OncologyOncologyMedicineNeoadjuvant LetrozolePathologyBreast CancerMetabolic ResponseCancer TreatmentPharmacologyRadiation OncologyEndocrine-related CancerCancer MetabolismPilot Study